About This Calculator
This Zilbrysq (zilucoplan) Dosing Calculator is designed for healthcare professionals to determine the appropriate weight-based daily dosage for adult patients with generalized myasthenia gravis (gMG). The tool simplifies dose selection according to the approved prescribing information by calculating the required dose and injection volume based on patient weight.
Outputs
After entering the patient’s weight and selecting the unit of measurement, the calculator provides the following key outputs:
- Recommended Daily Dose: The precise dose in milligrams (mg) for daily subcutaneous administration.
- Required Injection Volume: The corresponding volume in milliliters (mL) to be administered.
- Patient Weight Category: The weight bracket the patient falls into, which determines the dose selection.
How to Use
To use the calculator, follow these simple steps:
- Enter Patient Weight: Input the patient’s current body weight into the designated field.
- Select Units: Choose either kilograms (kg) or pounds (lbs) as the unit of weight.
- View Results: The calculator will automatically compute and display the recommended daily dose and injection volume. A “Calculate” button is also available for manual computation.
Dosing Overview
The recommended dosage of Zilbrysq is administered once daily via subcutaneous injection and is based on the patient’s actual body weight. The dosing schedule is categorized into three tiers.
| Patient Body Weight | Recommended Daily Dose | Injection Volume |
|---|---|---|
| Less than 56 kg | 24.3 mg | 0.6 mL |
| 56 kg to less than 77 kg | 32.4 mg | 0.8 mL |
| 77 kg or greater | 43.2 mg | 1.04 mL |
Switching
There is no specific guidance on switching from other gMG therapies to Zilbrysq. Clinical judgment should be used when transitioning a patient. Consider the half-life and mechanism of action of the prior therapy to avoid overlapping immunosuppression or a gap in treatment efficacy. Refer to the full prescribing information for complete details.
Missed Dose
If a dose of Zilbrysq is missed, instruct the patient to administer the dose as soon as possible. After that, they should resume their regular daily dosing schedule. Do not administer two doses to make up for a missed dose.
Safety Alerts
BOXED WARNING: SERIOUS MENINGOCOCCAL INFECTIONS. Zilbrysq, a complement inhibitor, increases a patient’s susceptibility to serious and life-threatening meningococcal infections caused by Neisseria meningitidis. Vaccinate patients against meningococcal serogroups A, C, W, Y, and B at least 2 weeks prior to administering the first dose, unless the risks of delaying therapy outweigh the risks of developing an infection. Monitor all patients for early signs and symptoms of meningococcal infection and evaluate immediately if infection is suspected.
FAQ
Zilbrysq is administered as a subcutaneous (under the skin) injection, once daily. Patients or caregivers can be trained to perform the injection at home.
No. This tool is intended for use in adult patients with generalized myasthenia gravis. The safety and effectiveness of Zilbrysq have not been established in pediatric patients.
According to the prescribing information, patients weighing 77 kg or more should receive the 43.2 mg daily dose.
No dose adjustment is required for patients with renal impairment or mild to moderate hepatic impairment. Zilbrysq has not been studied in patients with severe hepatic impairment.
The calculator internally converts pounds (lbs) to kilograms (kg) to determine the correct dosing tier. Selecting the correct unit is critical for an accurate calculation.
Patients must be vaccinated against meningococcal infections (serogroups A, C, W, Y, and B) at least two weeks before starting treatment, as specified in the boxed warning.
No, this is a clinical dosing aid only. It does not provide information on medication supply, number of syringes to prescribe, or insurance coverage.
This calculator does not provide information on drug interactions. Please consult the full prescribing information for a comprehensive list of potential interactions and contraindications.
References
- ZILBRYSQ (zilucoplan) Prescribing Information. U.S. Food and Drug Administration. Revised: 10/2023.
- Zilbrysq (zilucoplan) Summary of Product Characteristics. European Medicines Agency.
- Zilbrysq (zilucoplan) Healthcare Professional Site. UCB, Inc.
- Howard, J. F., et al. (2023). Zilucoplan for generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Neurology, 22(7), 582-593. https://doi.org/10.1016/S1474-4422(23)00155-2
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com